This grant is funded by Michael McKean in honor of Lee Grayson.
One strategy to target multiple myeloma is using a patient's immune system to target the tumor. However, myeloma cells can evade the immune
system. Therefore, new drugs are being studied that can activate the
immune system and enhance anti myeloma activity. In this project, Dr.
Menu and colleagues will use the ST33MM mouse model to test a new
activator of NKT (natural killer T-lymphocytes) cells preclinically. They will first characterize the NKT population in these mice and test their functionality against ST33MM cells and a CD1d transduced ST33MMvt cell line. They will then compare the efficiency of a new analogue in its capacity to activate NKT cells and reduce myeloma burden both in vitro and in vivo. This study will provide a potential new approach for immunotherapy in myeloma.